Clinical Trials Logo

Ovarian Cancer clinical trials

View clinical trials related to Ovarian Cancer.

Filter by:

NCT ID: NCT05215574 Recruiting - Breast Cancer Clinical Trials

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Start date: March 31, 2022
Phase: Phase 1
Study type: Interventional

Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NCT ID: NCT05211557 Recruiting - Ovarian Cancer Clinical Trials

Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer

Start date: November 16, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is single center, open-label phase I, non-randomized study which will enroll patients with recurrent advanced ovarian cancer to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T cells (fhB7H3.CAR-Ts) via using a '3+3+3' dose escalation design. In the dose expansion cohort, six patients will be enrolled to further assess their efficacy with the optimal dosage.

NCT ID: NCT05206890 Recruiting - Ovarian Cancer Clinical Trials

A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer

Start date: January 14, 2022
Phase:
Study type: Observational [Patient Registry]

Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in gynecologic malignancies, the majority of patients have advanced diseases at the time of diagnosis. This observational study is to evaluate the safety and efficacy of fluzoparib in ovarian cancer patients under real conditions, especially in various subgroups of ovarian cancer patients, in order to provide information about treatment modes for ovarian cancer patients in real-world diagnosis and treatment, and preliminarily evaluate the pharmacoeconomic of fluzoparib in the treatment of ovarian cancer.

NCT ID: NCT05204342 Completed - Ovarian Cancer Clinical Trials

Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France

Pro-TOCa
Start date: January 1, 2012
Phase:
Study type: Observational

Evaluation of the following prognostic factors in France, based on national quotation data: volume per center, patient age, geographic distance from a clinical center, delay for chemotherapy,Upfront surgery.

NCT ID: NCT05201001 Withdrawn - Ovarian Cancer Clinical Trials

APX005M in Patients With Recurrent Ovarian Cancer

APX005M
Start date: September 7, 2023
Phase: Phase 2
Study type: Interventional

The overall objective is to demonstrate preliminary efficacy of APX005M-carboplatin-PLD and APX005M-radiotherapy-carboplatin-PLD combinations as treatment for relapsed BRCAwt ovarian cancer patients, where platinum combination therapy is an option.

NCT ID: NCT05200364 Active, not recruiting - Ovarian Cancer Clinical Trials

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Start date: March 22, 2022
Phase: Phase 1
Study type: Interventional

Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.

NCT ID: NCT05200260 Not yet recruiting - Ovarian Cancer Clinical Trials

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Start date: February 2022
Phase: Phase 2
Study type: Interventional

Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer

NCT ID: NCT05198804 Recruiting - Ovarian Cancer Clinical Trials

A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Start date: January 27, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 study to evaluate the safety, clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib in subjects with platinum-resistant ovarian cancer.

NCT ID: NCT05194735 Active, not recruiting - Colorectal Cancer Clinical Trials

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Start date: April 4, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors

NCT ID: NCT05187208 Not yet recruiting - Ovarian Cancer Clinical Trials

PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer

POLO
Start date: January 2022
Phase: Phase 4
Study type: Interventional

This study is the phase IV, open-label, clinical trial to determine the efficacy of niraparib maintenance therapy in BRCA1/2 wild-type, advanced-stage, low-risk, primary ovarian cancer patients.